Evaluating the Safety and Efficacy Civamide in Osteoarthritis (OA) of the Knee(s)

2014-08-27 03:18:40 | BioPortfolio


To evaluate the safety and efficacy of Civamide Cream 0.075% as a treatment of the signs and symptoms associated with osteoarthritis of the knee.


To ensure that both subjects and investigators remain blinded, the following design will be employed:

1. Subject Blinding: Randomization Subjects will be blinded to assignment to the placebo or active study drug: One half of the subjects will be randomized to Civamide Cream 0.075% to be applied on the Target Knee 3 times daily for 84 days (12 weeks). The other half will be randomized to Placebo Cream to be applied on the Target Knee 3 times daily for 84 days (12 weeks).

As both Civamide Cream 0.075% and Placebo Cream can initially produce burning and stinging in some subjects, blinding to treatment assignment will be maintained. As the study progresses, the frequency of burning and stinging of both Civamide Cream 0.075% and Placebo Cream are expected to substantially decrease and be similar.

2. Investigator Blinding: Separate Raters To further maintain the blind, there will be two separate study staff raters: the Efficacy Rater Physician must be a physician-investigator who will evaluate efficacy parameters. The Safety Rater Physician must also be a physician-investigator who will evaluate safety parameters. A physician-investigator is defined as a physician who is listed as Principal Investigator or Sub-Investigator on Form FDA 1572. Each may assign a designee (another appropriately trained study staff member) to perform study procedures (as defined in Section 8.0 or Appendix E, for the Study Staff Responsibility Chart).

Study Periods:

See Study Flow Chart and Schedule of Observations.

Screening Period (Day -3):

The following procedures will be conducted: Obtain informed consent; assess eligibility according to selection criteria; collect demographic data, medical history, osteoarthritis history and diagnosis, and prior and current medications information. Perform physical examination and obtain vital signs and laboratory tests (chemistry, hematology & urinalysis). Female subjects of child-bearing potential will be given a urine pregnancy test. The subject will complete the Screening Pain Scale for both knees. Either Rater Physician will determine the subject's Functional Capacity Classification. If the subject is eligible, (i.e., Screening Pain Subscale score of ≥ 9 in one knee, subject does not have regular, significant pain due to OA or other conditions in the other knee, and has a Functional Capacity Classification score of I-III) the Efficacy Rater Physician or Safety Rater Physician will identify the knee joint with the most severe symptoms of OA as the "Target Knee". The subject must have an x-ray or radiographic report available within the last 3 years in order to meet the Selection Criteria. If the subject has no prior x-ray or radiographic report an x-ray of the Target Knee will be obtained.

Baseline/Randomization Period (Day 1) Either Rater Physician will review laboratory test and x-ray results of the Target Knee prior to randomization and confirm subject's continued eligibility including compliance with stability of the oral NSAIDs/COX-2 medications prior to randomization.

Subjects will complete another Screening Pain Scale to confirm that the Target Knee score is > 9. If eligible, the subject will be randomized into the Double-Blind Treatment Period.

If the Screening Pain Scale score is less than 9, the subject may return within 14 days of the first clinic visit (Visit 1/Day -3) to repeat it. If eligible at that time, the scheduled Baseline procedures will be performed and completed.

Eligible subjects will complete the WOMAC OA Index, the Subject's Global Evaluation, and the SF-36® Health Survey.

Subjects will apply their first dose of study drug in the clinic. They will be sent home with diaries to complete everyday, and with study drug that will be applied only on the Target Knee three times daily.

Treatment Period (Days 1-84):

The subject will complete the WOMAC OA Index and Subject's Global Evaluation at clinic visits on Days 1, 21, 42, 63 and 84 (not Day 3). Concurrent medications, adverse events, and study drug compliance will be reviewed and recorded by the Safety Rater Physician or designee throughout the Treatment Period at clinic visits on Days 3, 21, 42, 63 and 84 (End-of-Study/Final Visit).

Also on Day 84 (End-of-Study/Final Visit), the subject will complete the SF-36® Health Survey, the Efficacy Rater Physician will determine the Functional Capacity Classification, the Safety Rater Physician or designee will complete a final set of vital signs and collect laboratory samples. The Safety Rater Physician will perform a complete physical examination on each subject and will review laboratory results when available.

Safety Rater Physician or designee will contact the subject by phone on Days 15, 36, 57 and 78 to assess subject compliance with study drug application, maintenance of concurrent medications, including stable dose of NSAIDS or COX-2 inhibitors, review adverse events experienced, determine if subject has enough study drug to last until the next visit, and remind the subject of the next scheduled clinic visit.

On Day 84 (End-of-Study/Final Visit) the subject will be discharged after all procedures have been completed.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Osteoarthritis of the Knee


Civamide (Zucapsaicin)




Winston Laboratories

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:18:40-0400

Clinical Trials [1837 Associated Clinical Trials listed on BioPortfolio]

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive su...

Civamide Patch Safety, Tolerability and PK Study

To evaluate the tolerability of two different strengths of a Civamide Patch (0.0075% and 0.0150%) compared to the placebo patch and each other in healthy adult volunteers. To assess the p...

Civamide in OA of the Knee(s)

The purpose of this study is to evaluate the safety of Civamide Cream 0.075% as a Treatment in Subjects with Osteoarthritis (OA) of the Knee(s).

Oral Civamide Safety, Tolerability First in Human Study

Safety and pharmacokinetic first-time-in-human study of orally administered civamide in healthy subjects.

The Right Treatment for the Right Patient at the Right Time. A Study Following 5,000 Patients With Knee Osteoarthritis

The treatment that patients with knee OA are offered varies largely. There is a need for more evidence-based individualized guidance to treatment choice for knee osteoarthritis. This study...

PubMed Articles [1576 Associated PubMed Articles listed on BioPortfolio]

Combined effects of knee brace, laterally wedged insoles, and toe-out gait on knee adduction moment and fall risk in moderate medial knee osteoarthritis patients.

Knee osteoarthritis is a major contributor to the global burden of disease. There is a need of reducing knee joint load and to improve balance and physical function among knee osteoarthritis patients.

Associations between the chemokine biomarker CCL2 and knee osteoarthritis outcomes: The Johnston County Osteoarthritis Project.

Our study analyzes the association between chemokine-ligand-2 (CCL2) serum concentrations at baseline and knee radiographic OA (knee-rOA), knee-rOA progression, individual radiographic features and kn...

What are the clinical implications of knee crepitus to individuals with knee osteoarthritis? An observational study with data from the Osteoarthritis Initiative.

Crepitus is a common clinical feature of knee osteoarthritis. However, the importance of crepitus in the overall clinical presentation of individuals with knee osteoarthritis is unknown.

A naturally ageing knee, or development of early knee osteoarthritis?

To study the development of early knee osteoarthritis (OA) in subjects with and without risk factors for knee OA.

Thresholds of ultrasound synovial abnormalities for knee osteoarthritis - a cross sectional study in the general population.

To establish "normal" ranges for synovial thickness and effusion detected by ultrasound (US) and to determine cut-offs associated with knee pain (KP) and radiographic knee osteoarthritis (RKOA) in the...

Medical and Biotech [MESH] Definitions

Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)

An instrument used to assess the results of rehabilitation from knee injuries, especially those requiring ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION. It measures recovery of knee joint function based on ACTIVITIES OF DAILY LIVING.

Injuries to the knee or the knee joint.

A region of the lower extremity immediately surrounding and including the KNEE JOINT.

Replacement for a knee joint.

More From BioPortfolio on "Evaluating the Safety and Efficacy Civamide in Osteoarthritis (OA) of the Knee(s)"

Quick Search


Relevant Topics

Arthritis is by definition the inflammation of one or more joints, characterized by swelling, pain, warmth, redness and diminished range of joint movement (Oxford Medical Dictionary). There are many different types; Noninflammatory; Osteoarthritis, N...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Searches Linking to this Trial